Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts

International Journal of Cancer

Volumn 122, Issue 7, 2008, Pages 1585-1591

  Theurillat, Jean Philippe ^a   Zürrer Härdi, Ursina ^a   Varga, Zsuzsanna ^a   Barghorn, André ^a   Saller, Elisabeth ^a   Frei, Claudia ^a   Storz, Martina ^a   Behnke, Silvia ^a   Seifert, Burkhardt ^b   Fehr, Mathias ^a   Fink, Daniel ^a   Rageth, Christoph ^c   Linsenmeier, Claudia ^a   Pestalozzi, Bernhard ^a   Chen, Yao Tseng ^d   Knuth, Alexander ^a   Jäger, Dirk ^a,e   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Center for Breast Cancer   (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast cancer; In situ hybridization; NY BR 1; Tamoxifen; Tissue microarray

Indexed keywords

AROMATASE INHIBITOR; DIFFERENTIATION ANTIGEN; ESTROGEN RECEPTOR ALPHA; GONADORELIN AGONIST; MESSENGER RNA; TAMOXIFEN; TRANSCRIPTION FACTOR; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BREAST CANCER ANTIGEN NY BR 1, HUMAN; BREAST CANCER ANTIGEN NY-BR-1, HUMAN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER RECURRENCE; CELL TYPE; EXON; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SPERMATOCYTE; SPERMATOGENESIS; TESTIS TUMOR; TISSUE MICROARRAY; BREAST; BREAST TUMOR; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; PROSTATE TUMOR; TESTIS;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; RNA, MESSENGER; TAMOXIFEN; TESTICULAR NEOPLASMS; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 39649108663     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23241     Document Type: Article

References (26)

1. Jäger D, Stockert E, Gure AO, Scalan MJ, Karbach J, Jager E, Knuth A, Old LJ, Chen YT. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001;61:2055-61.
2. Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old LJ, Knuth A, Jager D, Moch H. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 2006;12:2745-51.
3. Theurillat JP, Zürrer-Härdi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, et al. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007;56:1723-31.
4. Jäger D, Taverna C, Zippelius A, Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 2004;53:144-7.
5. Jager D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jager E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005;5:11-18.
6. Wang W, Epler J, Salazar LG, Riddell SR. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 2006;66:6826-33.
7. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knueth A, Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases-correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 2007;120:2411-7.
8. Theurillat JP, Hainfellner J, Maddalena A, Weissenberger J, Aguzzi A. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am J Pathol 1999;154:581-90.
9. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-84.
10. Genomatrix Software GmbH MatInspector http: & genomatrix.de.
11. Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 2004;64:1632-8.
12. Vilar E, Calvo E, Tabernero J. Molecular biology of testicular germ cell tumors. Clin Transl Oncol 2006;8:846-50.
13. Satie AP, Raipert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Jacobsen GK, Rioux-Leclerq N, Jegou B, Samson M. The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest 2002;82:775-80.
14. Yuasa T, Okamoto K, Kawakami T, Mishina M, Ogawa O, Okada Y. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J Urol 2001;165:1790-4.
15. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721-47.
16. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence J Jr, MacMahon LP, Yue W, Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95:155-65.
17. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31.
18. Soubeyran I, Quenel N, Mauriac L, Durand M, Bonichon F, Coindre J-M. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 1996;73:735-43.
19. Lundgren S, Soreide JA, Lea OA. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer. Anticancer Res 1994;14:1313-16.
20. Murray PA, Gomm J, Ricketts D, Powles T, Coombes RC. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β 1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer A 1994;30:1218-22.
21. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 2004;150:243-55.
22. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab 2004;15:73-8.
23. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-17.
24. Saville B, Wormke M, Wang F, Nquyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000;275:5379-87.
25. Safe S. Transcriptional activation of genes by 17 β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231-52.
26. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-56.